Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
Publishing timestamp: 2024-05-07 15:48:16
Summary
Novo Nordisk and Eli Lilly's dominance in the weight loss drug market may face threats from rivals like Amgen, Viking Therapeutics, Altimmune, Structure Therapeutics, AstraZeneca, and others. Amgen's drug MariTide could potentially disrupt the market with less frequent dosing and longer-lasting weight loss. Other companies are also progressing with their own weight loss treatments, creating a competitive landscape in the growing market.
Sentiment: MIXED
Tickers: ZEAL-DK, AZN, NVO, NOVO.B-DK, UNDEFINED, LLY, AZN-GB, VKTX, ALT, AMGN,
Keywords: robert bradway, breaking news, health care industry, astrazeneca plc, pharmaceuticals, eli lilly and co, amgen inc, business, business news, biotech and pharmaceuticals, science, viking therapeutics inc, biotechnology, structure therapeutics inc, zealand pharma a/s, novo nordisk a/s, altimmune inc,